Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Codexis, Inc. (CDXS)

    1.0450 -0.1450 (-12.18%)
    At close: 4:00:01 PM EST
    1.0300 -0.0150 (-1.44%)
    After hours: 5:05:19 PM EST
    Trade Codexis on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for CDXS
    • Previous Close 1.1900
    • Open 1.2000
    • Bid 0.8568 x 200
    • Ask 1.0500 x 100
    • Day's Range 1.0400 - 1.2200
    • 52 Week Range 0.9600 - 2.9800
    • Volume 1,128,708
    • Avg. Volume 934,301
    • Market Cap (intraday) 114.434M
    • Beta (5Y Monthly) 2.39
    • PE Ratio (TTM) --
    • EPS (TTM) -0.3300
    • Earnings Date Nov 12, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 6.14
    • Zacks Rating Neutral

    Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

    www.codexis.com

    146

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Codexis, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    CDXS
    35.89%
    S&P 500 (^GSPC)
    10.17%

    1-Year Return

    CDXS
    55.91%
    S&P 500 (^GSPC)
    10.25%

    3-Year Return

    CDXS
    41.94%
    S&P 500 (^GSPC)
    74.66%

    5-Year Return

    CDXS
    96.90%
    S&P 500 (^GSPC)
    62.86%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 14.91M
    Earnings -12.01M
    Profit Margin -80.49%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    0
    20M
    -200.0%
    -150.0%
    -100.0%
    -50.0%
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    2.00
    6.14 Average
    1.0450 Current
    11.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 8/17/2026
    Analyst Piper Sandler
    Rating Action Maintains
    Rating Overweight
    Price Action Lowers
    Price Target 9 -> 8
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -39.55%

    • Return on Assets (ttm)

      -11.74%

    • Return on Equity (ttm)

      -69.36%

    • Revenue (ttm)

      77.68M

    • Net Income Avi to Common (ttm)

      -30.72M

    • Diluted EPS (ttm)

      -0.3300

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      54.92M

    • Total Debt/Equity (mrq)

      220.24%

    • Levered Free Cash Flow (ttm)

      2.13M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    CDNA CareDx, Inc.
    86.97 -0.50%
    FATE Fate Therapeutics, Inc.
    2.0155 -3.10%
    PSNL Personalis, Inc.
    15.76 -0.38%
    VCYT Veracyte, Inc.
    49.00 -2.02%
    CLLS Cellectis S.A.
    1.0350 -3.70%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: